For people doing well with HAART - A gene therapy that looks promising

The study is intended for individuals who are doing well on HAART therapy. In Step 1 of the trial, individuals will be given up to 6 infusions of the study drug VRX496 to see the effect on viral load and CD4 counts. If individuals have no serious adverse effects from the infusions of VRX496 and the viral load and CD4 counts remain stable, they may go on to Step 2 of the study. In Step 2, individuals will stop taking their HAART medication and their viral load, CD4 counts and the number of VRX496 in T cells will be monitored.

Full information is listed at the following link...

http://www.clinicaltrials.gov/ct/show/NCT00295477;jsessionid=C499FE55D717DC6853FACA55374345FC?order=1

Are you or do you know of anyone involved in this study? It would be great to hear from you! Also - if anyone has any additional information or insight, please share!

Be Well